Eisai looking to cash in on Japan’s increasing generics use

Japan biosimilars

Eisai is looking to cash in on Japan’s new affinity for generic drugs by doubling its Indian active pharmaceutical ingredients. Eisai will be expanding production to accommodate for the increase in demand for generic drugs in the Japanese market. Eisai will be producing APIs for about 10 different pharmaceutical products.

Read the source article at Pharma Manufacturing

About the Author

Related Posts

Leave a Reply